1. Zawistowski JS et al. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. Cancer Discovery. 2017 Jan 20.
  2. Crowe LB et al. A fluorescent Hsp90 probe demonstrates the unique association between extracellular Hsp90 and malignancy in vivo. ACS Chem Biol. 2017 Jan 19.


  1. Bowerman CJ et al. Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. Nano Lett. 2016 Dec 22.
  2. Alwarawrah Y et al. Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol. 2016 Jun 23;26(6):678-88.
  3. Cozzo AJ et al. cMET inhibitor crizotinib impairs angiogenesis and reduces tumor burden in the C3(1)-Tag model of basal-like breast cancer. Springerplus. 2016 Mar 19;5:348.
  4. Qin Y et al. Weight loss reduces basal-like breast cancer through kinome reprogramming. Cancer Cell Int. 2016 Apr 1;16:26.
  5. Souroullas GP et al. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nat Med. 2016 Jun;22(6):632-40.
  6. Usary J et al. Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes. Curr Protoc Pharmacol. 2016 Mar 18;72:14.38.1-11.


  1. Sancar A et al. Circadian clock, cancer, and chemotherapy. Biochemistry. 2015 Jan 20;54(2):110-23.
  2. Shelton SE et al. Quantification of Microvascular Tortuosity During Tumor Evolution Using Acoustic Angiography. Ultrasound Med Biol. 2015 Jul;41(7):1896-904.
  3. He Z et al. Poly(2-oxazoline) Based Micelles with High Capacity for 3rd Generation Taxoids: Preparation, In Vitro and In Vivo Evaluation. J Control Release. 2015 Jun 28;208:67-75.
  4. Carson CC et al. IL2 Inducible T-Cell Kinase, a Novel Therapeutic Target in Melanoma. Clin Cancer Res. 2015 May 1;21(9):2167-76.
  5. Karginova O et al. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 Apr;14(4):920-30. 
  6. Byrne JD et al. Local Iontophoretic Administration of Cytotoxic Therapies to Solid Tumors. Sci Transl Med. 2015 Feb 4;7(273):273ra14.
  7. Chandler RL et al. Coexistent ARID1A-PIK3CA Mutations Promote Ovarian Clear-Cell Tumorigenesis Through Pro-Tumorogenic Inflammatory Cytokine Signalling. Nat Commun. 2015 Jan 27;6:6118.


  1. Sundaram S et al. Obesity-Mediated Regulation of HGF/c-Met is Associated with Reduced Basal-like Breast Cancer Latency in Parous Mice. PLoS One. 2014 Oct 29;9(10):e111394. 
  2. Howe MK et al. Identification of an Allosteric Small-Molecule Inhibitor Selective for the Inducible Form of Heat Shock Protein 70. Chem Biol. 2014 Dec 18;21(12):1648-59.
  3. Song G et al. Effects of Tumor Microenvironment Heterogeneity on Nanoparticle Disposition and Efficacy in Breast Cancer Tumor Models. Clin Cancer Res. 2014 Dec 1;20(23):6083-95. 
  4. Burd C et al. Mutation-Specific RAS Oncogenicity Explains N-RAS Codon 61 Selection in Melanoma. Cancer Discov. 2014 Dec;4(12):1418-29.
  5. Sundaram S et al. Weight Loss Reversed Obesity-Induced HGF/c-Met Pathway and Basal-Like Breast Cancer Progression. Front Oncol., 2014 Jul 8;4:175.
  6. Sanoff H et al. Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer. J Natl Cancer Inst. 2014 Apr 1;106(4).
  7. Zhou B et al. Erythropoietin promotes breast cancer tumorigenesis through tumor initiating cell self-renewalJ Clin Invest. 2014 Feb 3;124(2):553-63.


  1. Chan K et al. Intravital imaging of a spheroid-based orthotopic model of melanoma in the mouse ear skin. 2013. IntraVital, 2:2, e25805. 
  2. Sundaram S et al. Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basallike breast cancer.  Breast Cancer Research and Treatment. 2013 Nov 12. 
  3. Usary JE et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res. 2013 June 18. 
  4. Burd C et al. Monitoring Tumorigenesis and Senescence In Vivo with a p16(INK4a)-Luciferase Model. Cell. 2013 Jan 17;152(1-2):340-51. 
  5. Kendellen MF et al. Canonical and Non-Canonical NF-κB Signaling Promotes the Function of Basal-Like Breast Cancer Tumor-Initiating Cells. Oncogene. 2013 Mar 11. 
  6. Hanna SC et al. HF1a and HIF2a independently activate SRC to promote melanoma invasion and metastases. J Clin Invest. 2013 Apr 8. 
  7. Anders C et al. Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer. Plos One. 2013 May 1. 


  1. Roberts PJ et al. Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy. J Natl Cancer Inst 2012;104:1–11. 
  2. Chen Z et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012 Mar 18;483(7391):613-7. 
  3. Duncan JS et al. Targeted MEK1/2 Inhibition Induces a Dynamic Reprogramming of the Kinome In Triple Negative Breast Cancer. Cell. Apr 2012 13;149(2):307-21. 
  4. The Collaborative Cross Consortium. The Genome Architecture of the Collaborative Cross Mouse Genetic Reference. Genetics. 2012 Feb; 190(2):389-401. 
  5. Roberts PJ et al. Combined therapy with PI3K/mTOR and MEK Inhibitors Exhibits Broad Anti-Tumor activity in Faithful Murine Cancer Models. Clin Cancer Res. 2012 Oct 1;18(19):5290-303.
  6. Liu W et al. LKB1/STK11 Inactivation Leads to Expansion of Pro-Metastatic Tumor Sub-Population in Melanoma. Cancer Cell. 2012 Jun 12;21(6):751-64.
  7. Kim WY and Sharpless NE. Drug Efficacy Testing In Mice. In Kinase Inhibitors and Cancer, I Mellinghoff and C Sawyers, eds. In Press, 19 type pages.
  8. Combest AJ et al. Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors. Oncologist. 2012 Sep 19. 


    1. Liu Y et al. Expression of p16INK4a prevents cancer and promotes aging in lymphocytes. Blood, 2011; 117:3257-67. 
    2. Cardenas JC et al. Overexpression of the cell cycle inhibitor p16INK4a promotes a prothrombotic phenotype following vascular injury in mice. Arterioscler. Thromb. Vasc. Biol., 2011, In Press. 
    3. Siamakpour-Reihani S et al. The Role of Calcineurin/NFAT in SFRP2 Induced Angiogenesis—A Rationale for Breast Cancer Treatment with the Calcineurin Inhibitor Tacrolimus. PLoS One. 2011;6(6):e20412. Epub 2011 Jun 3.
    4. Herschkowitz JI et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83. Epub 2011 Jun 1. 
    5. Russell RC et al. Loss of JAK2 regulation via VHL-SOCS1 E3 ubiquitin heterocomplex underlies chuvash polycythemia. Nat Med, 2011 Jun 19;17(7):845-53. 


      1. Carretero J et al. Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell. 2010;17:547-559. 
      2. Johnson SM et al. Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest. 2010;120:2528-2536. 
      3. Monahan KB et al. Somatic p16INK4a loss accelerates melanomagenesis. Oncogene. Aug. 9th, 2010. 
      4. Rozenberg GI et al. Metastasis in an orthotopic murine model of melanoma is independent of RAS/RAF mutation. Melanoma Res. 2010; 20:361-71 
      5. Kim WY et al. HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest, 2009; 119: 2160-70. 
      6. Li W et al. Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles. Mol Ther. May, 2008, 16:1252-60 
      7. Ji H et al. LKB1 modulates lung cancer differentiation and metastasis. Nature 2007; 448:807-810. 
      Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2778-83. Epub 2011 Jun 1.